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that vildagliptin 50 mg bid and sitagliptin 100 mg qd are equivalent is 99.3%. The 
result of a sensitivity analysis showed that the probability of the two drugs 
remaining equivalent remains high (>90%) over a wide range of MCIDs. 
CONCLUSIONS: This innovative method has the potential to improve 
understanding of equivalence (or non-inferiority) between drugs for multiple 
stake-holders.  
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OBJECTIVES: Applying propensity scores from confounders and their 
interactions, we observed the effect of reducing the number of digits for 
propensity score matching including resulting outcome point estimates. 
METHODS: We included sex, race, education, marital status, census region, year, 
age, insurance, and all pair-wise interactions for a 7 digit propensity score 
quantifying the conditional probability of low income status. Using 10 years of 
Medical Expenditure Panel Survey data, we assessed the association of low 
income status and experiencing an emergency room visit. We incrementally 
reduced matched propensity score digits from 7 to 2, observing effects on sample 
size, standardized differences in confounders, differences in covariate variance, 
odds ratio [OR] estimates, and Akaike Information Criterion [AIC]. RESULTS: 
Generally, fewer matching digits exacerbated differences in confounders 
between the matched sets. However, six digit matching was superior to  
seven-digit matching in confounder differences (standardized differences  
[SD] of 0 versus .01 respectively) as was 3 digit versus 4  
digit matching (SD of 3.39 versus 3.99 respectively). The pattern of variance 
differences was identical to the SD differences. Sample size was largest with 2 
digit matching (n=80,624), progressively diminishing with each additional  
digit matched (7 digit matching had n=61,168). AIC inflated inversely with digit 
reduction: 47,298.99 for 7 digit matching and 63,660.528 for 2 digit matching.  
ORs were consistent throughout (smallest OR=1.355 with 4 digits and largest 
OR=1.386 with 6 digits). CONCLUSIONS: Propensity score matching seeks  
to minimize differences between exposure groups. When propensity scores  
are generated using interaction terms, matching on a greater number of  
digits may not produce a better matched set of exposed and unexposed  
groups in terms of confounders. Analysts must consider the mechanism  
in which propensity scores are produced when specifying the matching 
algorithm.  
 
PRM205  
GENERATING DISTRIBUTIONS AND DATA: EVALUATING ONLINE, FREEWARE 
OPTIONS FOR HEALTH ECONOMIC MODELS  
McGhan WF, Willey VJ, Eapen K, Khole T 
University of the Sciences, Philadelphia, PA, USA  
OBJECTIVES: To evaluate an online, freeware JavaScript program that can be 
utilized in the generation and graphical illustration of alternative distributions 
and generate raw data for exploring cost effectiveness models. For this 
evaluation, beta, gamma and normal distributions were compared for a web-
based resource. METHODS: For evaluation, we compared the results between 
jStat.org and R statistical software. jStat is intended as a code library written in 
JavaScript that allows one to perform advanced statistical operations without the 
need of more resource intensive software (such as MS Excel or R). The jStat 
graphic and plotting functionality is based on the jQuery Flot plugin. RESULTS: 
Analysis of a mix of distributions from jStat (n = 100) versus R (n=100) found the 
following summary of results for the two-sample Kolmogorov-Smirnov test. Beta 
distributions (alpha = 8, beta = 2): (medians: 0.807 vs. 0.819) D = 0.16, p-value = 
0.549; gamma distributions (shape = 5, scale = 5): (medians: 23.5 vs. 26.9) D = 0.11, 
p-value = 0.581; and normal distributions (mean = 100, stdev = 10): (medians: 
101.6 vs. 101.3) D = 0.13, p-value = 0.366. CONCLUSIONS: jStat is designed to 
perform in most major browsers and operating systems. jStat applies 
complicated statistical functions that may be slower with handheld processors. 
There are a growing number of calculators on the internet that utilize JavaScript 
and java for the generation and plotting of such datasets. R and MS Excel remain 
popular and powerful resources that are frequently used in economic analyses 
and modeling that includes the generation of datasets with various statistical 
distributions. jStat may be useful for generating and examining pilot data or 
exploring the health economic ramifications of a clinical publication when the 
full patient dataset is not readily available.  
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OBJECTIVES: Studies that estimate incidence of very rare diseases (less than 1 in 
100,000 of the general population) often use cases seen at specialized centers. 
However, multiple potential sources of both systematic error and random error 
complicate this estimation. We calculated the incidence rate of Multicentric 
Castleman’s Disease (MCD) based on data from two specialized centers. Our 
objective is to describe the main challenges of incidence estimation of rare 
diseases in general, and specifically of MCD, and to suggest how to improve the 
assessment accuracy. METHODS: All the patients that were newly diagnosed 
with MCD at 2 centers were included. Patients’ locations were identified from the 
first 3 digit of their zip codes and mapped using a Geographical Information 
system (GIS). Catchment areas for each center were defined based on spatial 
patterns and center-specific clinician input. CENSUS data were used to estimate 
the size of the reference population and to calculate the crude and stratified 
incidence rates. RESULTS: Uncertainty resulted from small sample size; center-
specific population features and referral patterns; under-diagnosis and difficulty 
of diagnosis; association between disease risk factors and proximity to the 
centers; and difficulty with defining a catchment area to establish the relevant 
population denominator. Analysis involved a trade-off between the number of 
patients included in a catchment area and catchment area definition, with 
clearer geographical boundaries that maximized the proportion of MCD patients 
in the population represented in the center. CONCLUSIONS: Small sample sizes 
in combination with multiple potential sources of error challenge an accurate 
estimate of incidence. Finer definitions of each center catchment area further 
reduce the number of included cases but can improve the accuracy of the 
incidence estimate.  
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OBJECTIVES: the research aims to design and develop cost senstivity simulators 
both with intention and effective data on impact of economics on decision 
points in clinical practices. At this point mainly drug treatment and some 
diagnostic decisions with lab tests have been investigated. This step deals with a 
milestone to move from static to dynamic econometric modeling for reliable 
physicians’s cost awareness estimates on how patients ‘economic influence 
decisions, at the point of visits, for labtests and treatment decisions; by 
investigating various sources of changes in the survey. METHODS: several 
calibration issues are investigated following the first series of runs with the 
Physician National Ambulatory Medicare Survey. The analytical data sets used 
have been designed on diabetes, hypertension and asthma. Populations are 
identified with ICD codes, drug lists are also used to ascertain the population 
under study. Drug treatments are identified with drug codes, originally from the 
NDC and generic codes; the successive analytical datasets extracted from the 
NAMCS physician survey are used to estimate reliable estimates on impact of 
insurance and payment/billing systems, controlling for changes due to drug 
codes, ICD classification, categorization of patients, stages of computerization of 
EHRs, including reports on lab and diagnostic tests. RESULTS: The test of the 
dynamic modeling to adjust over time the disease models will lead to a synopsis 
of the different results from studies initiated since 2003. Comparison of results 
across three diseases already demontrate the consistency of the effects of the 
selected variables on insurance and payment or billing. It allows to identify 
conditions of replicability of the survey designs and to quantify the scope of 
biases. CONCLUSIONS: This stage of development will lead to propose reliable 
adjustement methods to integrate the various changes affecting the physician 
survey and the constitution of reliable analytical datasets extracted from that 
survey on major chronic conditions.  
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OBJECTIVES: Immortal time bias (ITB), the inclusion of person-time during 
which the study outcome cannot occur, has been shown to bias study findings. 
We examine the impact of ITB by estimating the effect of chemotherapy  
on overall survival, and demonstrate how landmark analysis can correct  
the bias. METHODS: Retrospective study using the MarketScan® Research 
Databases with commercially and Medicare insured individuals linked to the 
Social Security Administration Death records. Subjects with newly diagnosed 
metastatic breast cancer (ICD-9-CM 174.x plus additional codes 196.xx-199.xx) 
and ≥1 year of continuous enrollment prior to breast cancer diagnosis were 
identified. Chemotherapy exposure was defined as ≥3 chemotherapy claims 
following metastatic cancer diagnosis. Landmark analysis was used to estimate 
survival rates conditional on surviving to certain time points to adjust for  
ITB. Time to death or censoring was determined for the full sample and patients 
who survived 1, 3, 6 and 12 months. RESULTS: A total of 5759 metastatic breast 
cancer patients were identified of which 2932 had ≥3 claims for chemotherapy 
during follow-up. Average survival time for chemotherapy patients was 9.0 
months longer than patients with <3 chemotherapy claims. The difference in 
survival times between patients with and without chemotherapy decreased as 
patients were required to survive for longer periods of time: 1-month survival = 
+8.9 months, 3-month survival = +7.0 months, 6-month survival = +6.7 months, 
12-month survival = +7.0 months. The artificially increased effect of 
chemotherapy in the full sample analysis was due to the time between 
metastatic cancer diagnosis and third chemotherapy claim being “immortal” for 
the chemotherapy patients (median 2.6 months). CONCLUSIONS: Landmark 
analysis can be used to account for immortal time bias in oncologystudies 
analyzing the effect of new treatments or the comparative effectiveness of 
current treatments. However, an appropriate landmark must be chosen as 
results can be affected.  
